Metagenomi, Inc. Common Stock
MGX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $52 | $45 | $17 | $0 |
| % Growth | 16.8% | 160.2% | 6,978.2% | – |
| Cost of Goods Sold | $0 | $94 | $2 | $0 |
| Gross Profit | $52 | -$50 | $15 | -$0 |
| % Margin | 100% | -110.9% | 89.9% | -59.3% |
| R&D Expenses | $109 | $94 | $43 | $14 |
| G&A Expenses | $32 | $29 | $19 | $10 |
| SG&A Expenses | $32 | $29 | $19 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$94 | -$2 | -$0 |
| Operating Expenses | $141 | $29 | $60 | $24 |
| Operating Income | -$89 | -$78 | -$45 | -$24 |
| % Margin | -170% | -175.4% | -259.5% | -9,854.7% |
| Other Income/Exp. Net | $5 | $18 | $4 | $3 |
| Pre-Tax Income | -$84 | -$60 | -$41 | -$21 |
| Tax Expense | -$6 | $8 | $3 | $0 |
| Net Income | -$78 | -$68 | -$44 | -$21 |
| % Margin | -149.3% | -152.5% | -253.4% | -8,823.9% |
| EPS | -2.09 | -1.82 | -1.16 | -3.62 |
| % Growth | -14.8% | -56.9% | 68% | – |
| EPS Diluted | -2.09 | -1.82 | -1.16 | -3.62 |
| Weighted Avg Shares Out | 37 | 37 | 37 | 6 |
| Weighted Avg Shares Out Dil | 37 | 37 | 37 | 6 |
| Supplemental Information | – | – | – | – |
| Interest Income | $15 | $15 | $3 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $5 | $4 | $2 | $0 |
| EBITDA | -$83 | -$74 | -$39 | -$21 |
| % Margin | -159.7% | -166% | -227.9% | -8,540.3% |